UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Editorial: Impact of immunotherapy in lung cancer

Frontiers in oncology, 2022-11, Vol.12, p.1083524-1083524

2022

Volltextzugriff (PDF)

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.1690-1700

2016

Volltextzugriff (PDF)

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Clinical cancer research, 2018-06, Vol.24 (12), p.2771-2779

2018

Volltextzugriff (PDF)

Emerging Targets in Non-Small Cell Lung Cancer

International journal of molecular sciences, 2024-09, Vol.25 (18), p.10046

2024

Volltextzugriff (PDF)

Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach

Journal of thoracic oncology, 2021-02, Vol.16 (2), p.178-182

2021

Volltextzugriff (PDF)

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Volltextzugriff (PDF)

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

Clinical cancer research, 2019-10, Vol.25 (19), p.5832-5842

2019

Volltextzugriff (PDF)

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Cancer discovery, 2019-03, Vol.9 (3), p.384-395

2019

Volltextzugriff (PDF)

Diagnosis and Molecular Classification of Lung Cancer

Cancer treatment and research, 2016-01, Vol.170, p.25-46

2016

Volltextzugriff (PDF)

Lung Cancer Staging and Prognosis

Cancer treatment and research, 2016, Vol.170, p.47-75

2016

Volltextzugriff (PDF)

Prostaglandin E2 activates mitogen-activated protein kinase/erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner

Cancer research (Chicago, Ill.), 2005-07, Vol.65 (14), p.6275-6281

2005

Volltextzugriff (PDF)

Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer

Clinical lung cancer, 2022-01, Vol.23 (1), p.72-81

2022

Volltextzugriff (PDF)

Real-World Pseudoprogression: an Uncommon Phenomenon

Journal of thoracic oncology, 2018-07, Vol.13 (7), p.880-882

Reckamp, Karen L.

2018

Volltextzugriff (PDF)

Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States

Pharmaceutics, 2021-06, Vol.13 (6), p.912

2021

Volltextzugriff (PDF)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Clinical and translational science, 2022-05, Vol.15 (5), p.1143-1154

2022

Volltextzugriff (PDF)

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer

Clinical cancer research, 2019-08, Vol.25 (15), p.4691-4700

2019

Volltextzugriff (PDF)

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR )-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Frontiers in oncology, 2019-03, Vol.9, p.132-132

2019

Volltextzugriff (PDF)

Small Cell Lung Cancer

Cancer treatment and research, 2016, Vol.170, p.301-322

2016

Volltextzugriff (PDF)

Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network, 2018-05, Vol.16 (5S), p.601-604

Reckamp, Karen L.

2018

Volltextzugriff (PDF)

PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC

Molecular cancer research, 2014-05, Vol.12 (5), p.765-774

2014

Volltextzugriff (PDF)

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma

Lung cancer (Amsterdam, Netherlands), 2019-12, Vol.138, p.124-130

2019

Volltextzugriff (PDF)

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135

2015

Volltextzugriff (PDF)

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A

Journal of clinical oncology, 2022-07, Vol.40 (21), p.2295-2307

2022

Volltextzugriff (PDF)

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Journal of clinical oncology, 2019-02, Vol.37 (4), p.278-285

2019

Volltextzugriff (PDF)

1 – 25 von 268

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(257)
Mit Volltextzugriff
(234)

Publikationsform

Artikel
(250)
Buchkapitel
(16)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(268)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(130)
Life Sciences & Biomedicine
(128)
Humans
(110)
Oncology
(106)
Female
(48)
Male
(44)
Lung Neoplasms - Drug Therapy
(43)
Aged
(41)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(41)
Lung Cancer
(38)
Middle Aged
(38)
Lung Neoplasms - Pathology
(31)
Lung Neoplasms - Genetics
(29)
Aged, 80 And Over
(27)
Adult
(26)
Respiratory System
(26)
Mutation
(24)
Carcinoma, Non-Small-Cell Lung - Genetics
(22)
Carcinoma, Non-Small-Cell Lung - Pathology
(22)
Antineoplastic Agents - Therapeutic Use
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Editorial: Impact of immunotherapy in lung cancer

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Emerging Targets in Non-Small Cell Lung Cancer

Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Diagnosis and Molecular Classification of Lung Cancer

Lung Cancer Staging and Prognosis

Prostaglandin E2 activates mitogen-activated protein kinase/erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner

Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer

Real-World Pseudoprogression: an Uncommon Phenomenon

Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR )-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Small Cell Lung Cancer

Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer

PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Suchergebnisse filtern